News|Articles|October 1, 2026

EADV Congress 2026: Day 2 Recap—6 Headlines to Know

Check out highlights from news published on Day 2 of the EADV Congress 2026, spanning vitiligo, HS, atopic dermatitis, and more.

Day 2 of the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria, brought a broad mix of dermatology news spanning vitiligo, hidradenitis suppurativa, atopic dermatitis, palmoplantar pustulosis, and the dermatologic effects of a widely prescribed drug class.

Related to this article

November 13th, 2026

Omalizumab, Remibrutinib Show Similar Early CSU Gains in Indirect Analysis

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

November 12th, 2026

Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.

November 14th, 2026

Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.

November 14th, 2026

Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome

No patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026.

November 13th, 2026

ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema

Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.

November 12th, 2026

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.